Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about ESLA, unsubscribe in one click. Privacy
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Autologous Anti-CD19 AbTCR-expressing T- | B-Cell Non-Hodgkin's Lymphoma (NHL) | Phase 1/2 · NCT06343311 | Recruiting |
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
ESLA holds $100,000 in cash and short-term investments (as of Jun 30, 2026) and burns about $4.2M/quarter from operations, an estimated runway of 0.1 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 62 · High
As a result, management has determined that there is a substantial doubt about its ability to continue as a going concern.10-Q, Aug 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ESLA files for a raise →
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ESLA and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →